Cargando…
First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor
SAR445088 is an anti‐C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system and has the potential to provide clinical benefit in the treatment of complement‐mediated diseases. A phase I, first‐in‐human, double‐blind, randomized, place...
Autores principales: | Chow, Timothy, Shamszad, Pirouz, Vinnard, Christopher, Yoon, Esther, Belinski, Julia, Karpenko, Irene, Perrin, Laurent, Auwarter, Kristen, Storek, Michael, Surks, Howard, Wong, Nancy, Cohen, Yehuda Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087070/ https://www.ncbi.nlm.nih.gov/pubmed/36661084 http://dx.doi.org/10.1111/cts.13481 |
Ejemplares similares
-
High-density mapping of the slow pathway in a patient with atrioventricular nodal reentry given intranasal Etripamil during the NODE-1 study
por: Choe, William C., et al.
Publicado: (2017) -
Antibody-independent complement activation by myelin via the classical complement pathway
Publicado: (1982) -
Evidence for classic complement activity in neuromyelitis optica
por: Jones, Melina V., et al.
Publicado: (2014) -
A New Tool for Complement Research: In vitro Reconstituted Human Classical Complement Pathway
por: Mutti, Michele, et al.
Publicado: (2018) -
Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity
por: Gregersen, Emil, et al.
Publicado: (2021)